Navigation Links
New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation
Date:8/21/2008

rs state that this was an insufficient number of patients to validate the role of the ImmuKnow assay in monitoring risk for organ rejection. The mean ATP level of the three patients who underwent acute organ rejection was 247 +/- 193 ng/mL.

"We are pleased to see the data from this study support earlier published data on the use of the ImmuKnow assay in monitoring adult patients after a renal transplant," stated Brad L. Stewart, president of Cylex. "Clearly there is further research needed to elucidate the appropriate standards for use of cell-mediated immunity to monitor risk for infection and rejection in selected patient categories. However, this publication further illustrates the potential risks for infection associated with over-immunosuppression in renal transplant patients, and the potential value of the ImmuKnow assay in monitoring immune status."

*Sanchez-Velasco P, Rodrigo E, Valero R, et al. Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant. 2008;22:55-60.

About ImmuKnow(R)

ImmuKnow is the immune cell function assay cleared by the FDA to detect cell-mediated immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. The uses of the ImmuKnow assay as described in these studies have not been approved or cleared by the FDA. The Company may use data from these or similar studies to support future FDA marketing applications for similar indications.

About Cylex, Inc.

Cylex(TM) is a privately h
'/>"/>

SOURCE Cylex(TM)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
2. Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
3. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
4. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
5. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
6. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
7. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
8. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
9. Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
10. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
11. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and MARSEILLE, France , July 24, ... global license from University of Tokyo enables development of ... gene panels, for blood cancers  Mutations of ... favorable prognosis for patients with bone marrow disorders known ... developing companion diagnostics to guide treatment with new anti-cancer ...
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
(Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... Sept. 12, 2011 The National Association of ... that facilitates cooperation between law enforcement, healthcare professionals, ... prevention and investigation of drug diversion – today ... survey by the Substance Abuse and Mental Health ...
... HAYWARD, Calif., Sept. 12, 2011 Intarcia Therapeutics, ... abstracts on ITCA 650 (DUROS® subcutaneous continuous delivery ... diabetes at the 47th Annual Meeting of the ... Lisbon, Portugal.  All three presentations are scheduled for ...
Cached Medicine Technology:Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 2Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 3Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 4
(Date:7/25/2014)... Ireland (PRWEB) July 26, 2014 ... quality legal help to people who have suffered ... the launch of both their new company, and ... article on the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims ... law. The focus of the company is always ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 In recent ... about, and eager to reverse the symptoms associated with age-related ... the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. , ... 38-year-old father from Seattle who found himself beginning to feel ...
(Date:7/25/2014)... 2014 A federal judge has denied ... DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ) selected ... to go before a jury on September 1, 2014, ... July 18th, U.S. District Judge Ed Kinkeade of the ... claims may proceed to trial against Johnson & Johnson, ...
(Date:7/25/2014)... York, NY (PRWEB) July 25, 2014 ... ticket prices across the board for the Guinness International ... FC and Olympiacos FC at Soldier Field on ... also offering their customer appreciation promo/coupon/offer code SOCCER-2014 for ... an amazing year for diehard soccer fans in North ...
(Date:7/25/2014)... of America (GSA) the nation,s largest ... has chosen Heather M. Young, PhD, RN, ... the 2014 recipient of the Doris Schwartz Gerontological ... by GSA,s Health Sciences Section, is given to ... outstanding and sustained contribution to gerontological nursing research. ...
Breaking Medicine News(10 mins):Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... early stage ,breast cancer using Herceptin and chemotherapy, while ... drug known as an anthracycline, improves survival while posing ... tested three different regimens, one of which did not ...
... CHAPEL HILL, N.C. -- Cam Patterson, MD, MBA, division ... at Chapel Hill School of Medicine has been named ... Association Judah Folkman Award in Vascular Biology. The ... at mid-career (within fifteen years of their first faculty ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... can safely undergo MRIs to screen for cancer and ... a new study finds. Those procedures include only ... or later or defibrillators manufactured in 2000 or later, ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... mice whose symptoms closely mimic autism in humans. ... the mice in this study come closer to mirroring ... in humans, said senior study author Matthew Anderson, an ...
... WEDNESDAY, Oct. 5 (HealthDay News) -- A new oral drug ... rates and disability progression, according to the results of a ... one of the few oral drugs that treat this type ... for many MS patients, researchers said. "Basically, these ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. 5 ... listeria first linked to tainted cantaloupes has risen to 18, ... 20 states, the U.S. Centers for Disease Control and Prevention ... the cantaloupes in question were recalled Sept. 14, more cases ...
Cached Medicine News:Health News:Drug Combo Might Fight Aggressive Breast Cancer More Safely 2Health News:Drug Combo Might Fight Aggressive Breast Cancer More Safely 3Health News:MRI Safe With More Recent Defibrillators, Pacemakers: Study 2Health News:MRI Safe With More Recent Defibrillators, Pacemakers: Study 3Health News:Scientists Engineer Mice That Have Autism 2Health News:Scientists Engineer Mice That Have Autism 3Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 3
Inquire...
... work area that will help protect your ... irradiate the work area prior to use, ... be amplified. Containment features reduce the chance ... acrylic windows for a clear view, an ...
... x 24in(h). Designed to protect against ... The PCR Workstation irradiates the workspace prior ... airborne contamination by limiting exposure of experimental ... two fluorescent lights, one UV light, 12 ...
... Electropolished stainless steel ... mounts dampen vibration to ... as isolating vibration-producing equipment ... low-profile design allows for ...
Medicine Products: